AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02418585
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Induction Phase.
Trial: NCT04080752
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered orally.
Trial: NCT03018223
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Reduced intensity conditioning: 14.5 mg/kg/day on days -6, -5. GVHD prophylaxis: 50 mg/kg ideal body weight (IBW) daily dose will be given on days +3 and +4 post-transplant as an IV infusion over 1-2 hours.
Trial: NCT03434041
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will self-administer matching placebo as intranasal spray.
Trial: NCT04532749
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo tablets.
Trial: NCT02324309
Drug: BIOD-531
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02324309
Drug: Humalog Mix 75/25
RxNorm normalized name: HumaLOG Mix 75/25
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01575041
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (cellulose, provided by Microz, Geleen, Netherlands): 8 capsules per day.
Trial: NCT01328808
Drug: Acetaminophen/APAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In preterm and term neonates with a GA of 28 weeks or more a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute.~In preterm and term neonates with a GA of less than 28 weeks a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute
Trial: NCT04067011
Drug: Doxycycline 100Mg Tablet
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline 100mg administered by mouth every 12 hours. The antibiotic will be administered orally on Study Days 2-9, 22-24 and 32-38.
Trial: NCT03939481
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given chemotherapy regimen
Trial: NCT01489228
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT00828529
Drug: TMC207
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04228900
Drug: Systematic drug review
RxNorm normalized name: Integrase Inhibitors, antiinfectives for systematic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consider altering medication list if the patient has symptoms that may be attributed to adverse drug effects, in particular side effects as nausea, dry mouth or loss of appetite, and if drug-drug interactions or drug-disease interactions are likely to occur. Recommended changes in patient's medication list will be presented for the family physician who will hold the final decision to implement the suggested adjustments.
Trial: NCT00931008
Drug: SID530, Taxotere
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75mg/m2
Trial: NCT01834768
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02762539
Drug: omega-3 enriched SMOF lipid emusion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02652377
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to match EDP-494
Trial: NCT04488081
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral: 400 mg BID for 7 days.
Trial: NCT04126603
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection
Trial: NCT00321321
Drug: Sulfonylurea
RxNorm normalized name: Sulfonylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01425528
Drug: Sapropterin
RxNorm normalized name: Sapropterin
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sapropterin will be taken daily for 12 or 24 weeks. Starting dose will be 20mg/kg/day and will increase at the 8 week visit to 30 mg/kg/day. Dosing may be further increased to as high as 40 mg/kg/day in attempt to normalize BH4 levels in CSF. Starting dose for Cohort 2 will be determined from data analysis in Cohort 1.
Trial: NCT04372121
Drug: Placebo capsule to match Add-back capsule
RxNorm normalized name: PLACEBO CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For oral administration once daily
Trial: NCT03070327
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 3000 mg/m2 IV once on day -7 to -2 or low intensity cy/flu (cyclophosphamide 300 mg/m2/day x 3 + fludarabine 30 mg/m2/day x 3) with the last day occurring on day -7 to -2 are the default options for is the default conditioning chemotherapy.
Trial: NCT02877134
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo Subcutaneously.
Trial: NCT04022239
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01121484
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets taken orally once daily.
Trial: NCT03602261
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, weekly
Trial: NCT03885011
Drug: CSF-1
RxNorm normalized name: CSF-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This treatment arm consists of 2 different concentrations of CSF-1. Subjects randomized to the CSF-1 treatment arm will receive their first dose of CSF-1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 arm will now receive a different concentration of CSF-1. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
Trial: NCT03885011
Drug: CSF-1 Component #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This treatment arm consists of 2 different concentrations of CSF-1 Component #1.~Subjects randomized to the CSF-1 Component #1 treatment arm will receive their first dose of CSF-1 Component #1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #1 arm will now receive a different concentration of CSF-1 Component #1. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
Trial: NCT03885011
Drug: CSF-1 Component #2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This treatment arm consists of a single concentration of CSF-1 Component #2. Subjects randomized to the CSF-1 Component #2 treatment arm will receive their first dose of CSF-1 Component #2 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #2 arm will continue dosing with the same concentration of CSF-1 Component #2. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
Trial: NCT02081118
Drug: HM11260C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
Trial: NCT02081118
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for HM11260C
Trial: NCT03998683
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as SC injection.
Trial: NCT01947660
Drug: Systemic analgesia + Continuous regional anesthesia
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic analgesia + Continuous regional anesthesia, peri neural for the 2 to 4 first days post-operative
Trial: NCT01947660
Drug: Systemic analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic analgesia as usual
Trial: NCT03928145
Drug: Chlorthalidone 25 mg
RxNorm normalized name: chlorthalidone 25 MG
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 25 mg taken orally in the morning for 12 weeks.
Trial: NCT03928145
Drug: Amiloride 20 mg
RxNorm normalized name: amiloride 20 MG
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amiloride 20 mg taken orally in the morning for 12 weeks.
Trial: NCT03928145
Drug: Amiloride 10 mg
RxNorm normalized name: amiloride 10 MG
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amiloride 10 mg taken orally in the morning for 12 weeks.
Trial: NCT01617317
Drug: Hyperimmune intravenous immunoglobulin
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous infusion of 0.4g/kg of H1N1 2009 H-IVIG
Trial: NCT00779558
Drug: Heparin sulfate infusion at 10 units/kg/hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of heparin to prevent central line thrombosis in infants after cardiac surgery
Trial: NCT00779558
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of normal saline
Trial: NCT00791219
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two placebo capsules taken approximately 30 minutes prior to breakfast
Trial: NCT00931918
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide IV
Trial: NCT00931918
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin IV solution
Trial: NCT02569398
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One matching placebo tablet orally once daily up to 54 months.
Trial: NCT00640796
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide, Fludarabine, Interleukin-2, Mesna
Trial: NCT00525265
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be orally administered placebo once daily after breakfast for seven days.
Trial: NCT00073827
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo MDI QID
Trial: NCT02053545
Drug: Conditioning Regimen & GVHD Prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stratum 1 (Refractory disease, relapse after previous transplant): Radiation Therapy (if patient had prior Central Nervous System (CNS) disease), Clofarabine, Melphalan,Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus and MMF~Stratum 2 (Myeloid in remission): Radiation Therapy (if patient had prior CNS disease), Busulfan, Fludarabine, Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus, MMF~Stratum 3 (Lymphoid in remission): Radiation Therapy (if patient had prior CNS disease), TBI, Fludarabine, Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus, MMF
Trial: NCT02839707
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01108393
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01628848
Drug: SPM 962
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPM 962 transdermal patch once a daily up to 36.0 mg/day
Trial: NCT01628848
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo transdermal patch
Trial: NCT03227224
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 2 placebo capsules matching JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
Trial: NCT01960075
Drug: Fosphenytoin
RxNorm normalized name: Fosphenytoin
DrugBank: Fosphenytoin (DB01320)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02975297
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline.
Trial: NCT02406027
Drug: JNJ-54861911, 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will self-administer JNJ-54861911 tablet, 10 mg (2\*5 mg), orally, once daily.
Trial: NCT02406027
Drug: JNJ-54861911, 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will self-administer 1 tablet of JNJ-54861911, containing 25 mg orally, once daily.
Trial: NCT04461925
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: per os
Trial: NCT04461925
Drug: Hormones
RxNorm normalized name: Other hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a moderate amount of dexamethasone i/v
Trial: NCT04461925
Drug: Anticoagulant Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub-Q
Trial: NCT00129506
Drug: methotrexate + misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03782376
Drug: Placebo (SC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive SC injection of placebo at Week 0.
Trial: NCT01430078
Drug: ASP015K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT01430078
Drug: ASP015K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution via oral capsule
Trial: NCT03019198
Drug: Placebo - Concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00285493
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02780830
Drug: AZD2014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD2014 will be supplied as oral tablets. AZD2014 will be taken orally twice per day on an intermittent dosing schedule, 2 days on and 5 days off of each week.
Trial: NCT03782376
Drug: Placebo (IV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive IV infusion of placebo at Week 0.
Trial: NCT02659098
Drug: CNTO 2476 3.0 x 10^5 cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single subretinal administration of CNTO 2476 3.0 x 10\^5 cells in 50 microliter (mcL) given by subretinal Delivery System.
Trial: NCT00486135
Drug: XL147 (SAR245408)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatin capsules supplied in 25-mg and 100-mg dosage strengths
Trial: NCT00486135
Drug: XL147 (SAR245408)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets supplied as 100-mg, 150-mg, and 200-mg dosage strengths
Trial: NCT00274690
Drug: GW679769
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00262288
Drug: i.v. recombinant human C1 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03556358
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m\^2, 30 min IV infusion, every 3 weeks (Cycles 1-4)
Trial: NCT04487080
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo orally.
Trial: NCT03559192
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered as 2 capsules orally once daily.
Trial: NCT00198601
Drug: Gentamicin in Uniject Pre-filled syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02493868
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimization Phase: Transferred-entry participant will self-administer intranasal placebo at weekly treatment sessions for the first 4 weeks of this phase, then individualized to either once weekly or once every other week based on depressive symptoms. Maintenance Phase: Direct-entry and transferred-entry participants assigned to placebo will self-administer matching intranasal placebo once weekly or once based on depressive symptoms.
Trial: NCT00429442
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 mg once daily
Trial: NCT00429442
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: calcium tablets once daily
Trial: NCT03818035
Drug: Placebo Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants of group 2b will receive matching placebo injection subcutaneously at weeks 28, 44 and 60.
Trial: NCT03517722
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matching to ustekinumab IV or SC.
Trial: NCT02215954
Drug: Niflec
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niflec is a white-yellowish powder for oral solution. Each plastic sachet (137.155 g) contains sodium chloride 2.93 g, potassium chloride 1.485 g, sodium bicarbonate 3.37 g and sodium sulfate anhydrous 11.37 g, as well as macrogol 4000, saccharin sodium hydrate, flavour as excipients. Niflec is dissolved in water to make approximately 2 L of solution before administration.
Trial: NCT02714699
Drug: diclofenac potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will take oral diclofenac potassium; two tablets (cataflam 25 mg) and one tablet placebo one hour before the procedure
Trial: NCT02714699
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will take oral placebo; 2 tablets one hour before the procedure
Trial: NCT02638623
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional fluids will be administered
Trial: NCT03198793
Drug: QGC001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily (BID) administration of oral (PO) QGC001 (250 mg BID, 500 mg BID, and 500 mg BID + hydrochlorothiazide (HCTZ) 25 mg once daily \[QD\]) over 8 weeks.
Trial: NCT01657266
Drug: PRO-155
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-medication (before surgery) and maintenance treatment.
Trial: NCT02322814
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to cobimetinib will be administered orally, once a day, on Day 3 through Day 23 of each 28 day treatment cycle.
Trial: NCT03846414
Drug: PEG-rhG-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-rhG-CSF was administered 24 hours after the end of chemotherapy for each chemotherapy cycle.
Trial: NCT00004390
Drug: desipramine
RxNorm normalized name: Desipramine
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02053519
Drug: Active Comparator: Vigantol Oil (Vitamin D3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D Oral oil 100.000iu in 5 mls
Trial: NCT02053519
Drug: Mygliol Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo comparator
Trial: NCT01199159
Drug: Vitamin B 6
RxNorm normalized name: vitamin B 6 100 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg vitamin B6 given sublingually 30 minutes before total abdominal hysterectomy
Trial: NCT03253133
Drug: LV5FU or Folfiri
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Association of chemotherapy by LV5FU or Folfiri according pratician choice
Trial: NCT02422186
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will self-administer matching placebo, intranasally, twice per week for 4-weeks as a flexible dose regimen in the Double-Blind Induction Phase.
Trial: NCT02005783
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide:600mg/m2, d1, q3w\*4
Trial: NCT03448159
Drug: Fluoxetine Hydrochloride
RxNorm normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Half of the participants will take fluoxetine for a period of 15-17 weeks (depending on ramp-up period).
Trial: NCT03455218
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 ppm of Nitric Oxide gas delivered to the oxygenator for the duration of cardiopulmonary bypass
Trial: NCT03455218
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INOmax device connected to oxygenator, but no gas is delivered
Trial: NCT03311932
Drug: Infacort®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release multiparticulate formulation (granules) of hydrocortisone
Trial: NCT03311932
Drug: Cortef®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release hydrocortisone tablets
Trial: NCT01334762
Drug: CC/IUI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received 100 mg lCC daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
Trial: NCT00555204
Drug: ABT-089
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg - capsules once daily for 12 weeks
Trial: NCT00555204
Drug: ABT-089
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg - capsules once daily for 12 weeks
Trial: NCT00555204
Drug: ABT-089
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg - capsules once daily for 12 weeks
Trial: NCT00555204
Drug: ABT-089
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg - capsules once daily for 12 weeks
Trial: NCT00555204
Drug: ABT-089
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg - capsules once daily for 12 weeks